Altimmune, Inc. (ALT) vs Evolus, Inc. (EOLS)
A side-by-side comparison of Altimmune, Inc. and Evolus, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
EOLS
Evolus, Inc.
$7.47HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALT vs EOLS
growth of $100 · dividends reinvested · last 9yALT -94.2% (-27.1%/yr)EOLS -35.0% (-4.7%/yr)EOLS compounded faster over this window
Log scale — wide-divergence pair
ALT EOLS
ALT vs EOLS: by the numbers
- •ALT is the larger company ($519M vs $492M market cap).
- •Both run net losses; EOLS's is the smaller (-10.85% vs -296000.00% net margin).
- •EOLS grew revenue faster over the past five years (32.82% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | EOLS |
|---|---|---|
| P/S ratio | 16749.86 | 1.55 |
| P/B ratio | 1.09 | N/A |
Profitability
| Metric | ALT | EOLS |
|---|---|---|
| Gross margin | 100.00% | 66.25% |
| Operating margin | -230460.98% | -7.33% |
| Net margin | -296000.00% | -10.85% |
| ROE | -19.35% | N/A |
| ROIC | -19.47% | -15.54% |
Growth (annualized)
| Metric | ALT | EOLS |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 32.82% |
| Total return CAGR (5Y) | -25.30% | 0.46% |
Frequently asked
- Which has grown faster, ALT or EOLS?
- Over the past five years, EOLS grew revenue faster — ALT at a -65.38% CAGR versus EOLS at 32.82%.
- How have ALT and EOLS total returns compared?
- Over the past 5 years, ALT delivered -25.30% and EOLS delivered 0.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Altimmune ROEEvolus ROEAltimmune operating marginEvolus operating marginAltimmune revenue growthEvolus revenue growthAltimmune free cash flowEvolus free cash flow
Altimmune & Evolus appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.